MARC record from Internet Archive

LEADER: 02102cam 2200493 a 4500
001 ocm32926210
003 OCoLC
005 20200507212834.0
008 950418s1995 txua b 001 0 eng
010 $a 95142272
040 $aDLC$beng$cDLC$dBTCTA$dYDXCP$dNLM$dGUA$dUBA$dCGC$dDEBSZ$dCUS$dUBY$dUAB$dOCLCO$dOCLCF$dOCLCQ
016 7 $a9510717$2DNLM
019 $a32692183
020 $a3540588906
020 $a9783540588900
020 $a9781570591907
020 $a1570591903
035 $a(OCoLC)32926210$z(OCoLC)32692183
050 00 $aRM666.N87$bC76 1995
060 00 $a1995 G-213
060 10 $aQU 57$bC948t 1995
082 00 $a615/.7$220
100 1 $aCrooke, Stanley T.
245 10 $aTherapeutic applications to oligonucleotides /$cStanley T. Crooke.
260 $aAustin :$bR.G. Landes Co.,$c℗♭1995.
300 $a138 pages :$billustrations ;$c27 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aMedical intelligence unit
504 $aIncludes bibliographical references and index.
505 0 $a1. History -- 2. Molecular Mechanisms of Action of Oligonucleotides Designed to Interact with Nucleic Acids -- 3. The Selection of Optimal RNA Receptor Sites for Antisense Effects -- 4. First Generation Oligonucleotide Analogs Other than Phosphorothioates -- 5. Phosphorothioate Oligonucleotides -- 6. The Medicinal Chemistry of Oligonucleotides -- 7. Drug Delivery Issues and Systems -- 8. Experimental Caveats -- 9. Prospectus.
650 0 $aOligonucleotides$xTherapeutic use.
650 12 $aOligonucleotides, Antisense$xpharmacology.
650 22 $aOligonucleotides, Antisense$xchemistry.
650 7 $aOligonucleotides$xTherapeutic use.$2fast$0(OCoLC)fst01045458
650 7 $aFarmacologia.$2larpcal
830 0 $aMedical intelligence unit (Unnumbered)
938 $aBaker and Taylor$bBTCP$n95142272
938 $aYBP Library Services$bYANK$n100041967
029 1 $aAU@$b000011609700
029 1 $aNLM$b9510717
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 40 OTHER HOLDINGS